Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Nuance Acquires Rights to Novel COPD Therapy From Verona in $219 Million Deal

publication date: Jun 10, 2021

Shanghai Nuance Pharma acquired greater China rights to a novel COPD treatment from Verona Pharma of London in a $219 million deal. Ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4, offering both bronchodilator and anti-inflammatory effects. Verona is currently testing ensifentrine in a global Phase III trial as a maintenance treatment for chronic obstructive pulmonary disease. Nuance will make a $25 million upfront payment and a $15 million investment in Verona, plus milestones of up to $179 million and royalties. More details....

Stock Symbol: (NSDQ: VRNA)

Share this with colleagues:

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital